STAT+: Travere’s drug for a kidney disease doesn’t improve kidney function. The FDA approved it anyway

AI Briefing

• – FDA approves Travere's kidney disease drug despite disappointing clinical trial results.
• – Travere's drug showed no improvement in kidney function in patients with IgA nephropathy.
• – The FDA approved the treatment as a last resort for patients who have not responded to other treatments.